Literature DB >> 34003330

LKB1-PTEN axis controls Th1 and Th17 cell differentiation via regulating mTORC1.

Mahesh Pandit1, Maheshwor Timilshina1, Jae-Hoon Chang2.   

Abstract

Immuno-environmental change triggers CD4+ T cell differentiation. T cell specialization activates metabolic signal pathways to meet energy requirements. Defective T cell-intrinsic metabolism can aggravate immunopathology in chronic diseases. Liver kinase B1 (LKB1) deletion in T cell or Treg cell results in systemic inflammatory symptoms, indicating a crucial role of LKB1 in T cells. However, the mechanism underlying the development of inflammation is unclear. In our study, LKB1-deficient T cells were differentiated preferentially into Th1 and Th17 cells in the absence of inflammation. Mechanistically, LKB1 directly binds and phosphorylates phosphatase and tensin homolog (PTEN), an upstream regulator of mammalian target of rapamycin complex 1 (mTORC1), which is independent of AMP-activated protein kinase (AMPK). As a result, LKB1 deficiency was associated with increased mTORC1 activity and hypoxia-inducible factor (HIF)1α-mediated glycolysis. Inhibition of glycolysis or biallelic disruption of LKB1 and HIF1α abrogated this phenotype, suggesting Th1- and Th17-biased differentiation in LKB1-deficient T cells was mediated by glycolysis. Our study indicates that LKB1 controls mTORC1 signaling through PTEN activation, not AMPK, which controls effector T cell differentiation in a T cell-intrinsic manner. KEY MESSAGES: • LKB1 maintains T cell homeostasis in a cell intrinsic manner. • Glycolysis is involved in the LKB1-mediated T cell differentiation. • LKB1 phosphorylates PTEN, not AMPK, to regulate mTORC1.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Autoimmunity; Glycolysis; LKB1-PTEN; T cell

Mesh:

Substances:

Year:  2021        PMID: 34003330     DOI: 10.1007/s00109-021-02090-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  42 in total

Review 1.  CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.

Authors:  Kiyoshi Hirahara; Toshinori Nakayama
Journal:  Int Immunol       Date:  2016-02-12       Impact factor: 4.823

2.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Authors:  Greg M Delgoffe; Thomas P Kole; Yan Zheng; Paul E Zarek; Krystal L Matthews; Bo Xiao; Paul F Worley; Sara C Kozma; Jonathan D Powell
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

3.  Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of Treg Cells.

Authors:  Maheshwor Timilshina; Zhiwei You; Sonja M Lacher; Suman Acharya; Liyuan Jiang; Youra Kang; Jung-Ae Kim; Hyeun Wook Chang; Keuk-Jun Kim; Byoungduck Park; Jae-Hyoung Song; Hyun-Jeong Ko; Yun-Yong Park; Min-Jung Ma; Mahesh Raj Nepal; Tae Cheon Jeong; Yeonseok Chung; Ari Waisman; Jae-Hoon Chang
Journal:  Cell Rep       Date:  2019-06-04       Impact factor: 9.423

Review 4.  Regulation and function of mTOR signalling in T cell fate decisions.

Authors:  Hongbo Chi
Journal:  Nat Rev Immunol       Date:  2012-04-20       Impact factor: 53.106

5.  The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Authors:  David B Shackelford; Reuben J Shaw
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 6.  LKB1 and AMPK: central regulators of lymphocyte metabolism and function.

Authors:  Julianna Blagih; Connie M Krawczyk; Russell G Jones
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

Review 7.  Metabolic pathways in immune cell activation and quiescence.

Authors:  Erika L Pearce; Edward J Pearce
Journal:  Immunity       Date:  2013-04-18       Impact factor: 31.745

8.  LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis.

Authors:  M C Poffenberger; A Metcalfe-Roach; E Aguilar; J Chen; B E Hsu; A H Wong; R M Johnson; B Flynn; B Samborska; E H Ma; S-P Gravel; L Tonelli; L Devorkin; P Kim; A Hall; S Izreig; E Loginicheva; N Beauchemin; P M Siegel; M N Artyomov; J J Lum; G Zogopoulos; J Blagih; R G Jones
Journal:  Science       Date:  2018-07-27       Impact factor: 47.728

9.  The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.

Authors:  Greg M Delgoffe; Kristen N Pollizzi; Adam T Waickman; Emily Heikamp; David J Meyers; Maureen R Horton; Bo Xiao; Paul F Worley; Jonathan D Powell
Journal:  Nat Immunol       Date:  2011-02-27       Impact factor: 25.606

Review 10.  Dysregulation of mTOR activity through LKB1 inactivation.

Authors:  Wei Zhou; Adam I Marcus; Paula M Vertino
Journal:  Chin J Cancer       Date:  2013-05-14
View more
  2 in total

1.  AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway.

Authors:  Ram Hari Pokhrel; Suman Acharya; Jae-Hee Ahn; Ye Gu; Mahesh Pandit; Jong-Oh Kim; Yun-Yong Park; Ben Kang; Hyun-Jeong Ko; Jae-Hoon Chang
Journal:  Mol Cancer       Date:  2021-10-14       Impact factor: 27.401

2.  AMPK suppresses Th2 cell responses by repressing mTORC2.

Authors:  Mahesh Pandit; Maheshwor Timilshina; Ye Gu; Suman Acharya; Yeonseok Chung; Sang-Uk Seo; Jae-Hoon Chang
Journal:  Exp Mol Med       Date:  2022-08-23       Impact factor: 12.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.